Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold
Merck Co Inc (NYSE: MRK ) will initiate a new Phase 3 program with once-daily islatravir to treat people with HIV-1 infection. These new Phase 3 studies will evaluate a once-daily oral combination of doravirine 100 mg and a lower dose of islatravir (DOR|ISL). One study will evaluate DOR|ISL in previously untreated adults with HIV-1 infection, and two studies will evaluate DOR|ISL as a switch in antiretroviral therapy (ART) in adults with HIV-1 infection … Full story available on Benzinga.com
Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold
Merck Co Inc (NYSE: MRK ) will initiate a new Phase 3 program with once-daily islatravir to treat people with HIV-1 infection. These new Phase 3 studies will evaluate a once-daily oral combination of doravirine 100 mg and a lower dose of islatravir (DOR|ISL). One study will evaluate DOR|ISL in previously untreated adults with HIV-1 infection, and two studies will evaluate DOR|ISL as a switch in antiretroviral therapy (ART) in adults with HIV-1 infection … Full story available on Benzinga.com